A clinical study of azithromycin (AZM), a newly developed oral macrolide antibacterial agent, was performed with the following results. AZM at a dose of 250 or 500 mg was administered once a day for 3 days to 22 patients, including 1 case of pharyngolaryngitis, 4 of acute bronchitis and 17 of pneumonia. The clinical effect was evaluated as excellent in 5, good in 13, poor in 1 and undetermined in 3 cases. Adverse reactions thought to have a causal relationship to AZM included coughing, dyspnea and fever in 1 case and a rigidity of anterior chest in 1 case. However, these symptoms disappeared within 1 month after the administration of AZM. Abnormal laboratory values due to drug administration were observed in 3 cases: increased eosinophils in 2, elevated GOT, GPT, ALP, γ-GTP, CRP and ESR in 1.
|Number of pages||5|
|Journal||Japanese Journal of Chemotherapy|
|Publication status||Published - Jan 1 1995|
All Science Journal Classification (ASJC) codes
- Pharmacology (medical)